Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Asthma Severity in Women: The Influence of Training and Menopause (ATOM)

17 giugno 2021 aggiornato da: Vibeke Backer, Rigshospitalet, Denmark

The ATOM Study: Asthma Severity in Women: The Influence of Training and Menopause

Introduction: Late-onset asthma in women is characterized by poor disease control and reduced quality of life despite intensive treatment with inhaled steroid and beta2-agonist. The condition is further worsened at menopause due to the loss of estrogen leading to increased asthma exacerbation frequency, increased airway inflammation and decreased lung function. Exercise training may increase disease control of asthma patients, but to what extent the same effect is seen in postmenopausal women with late-onset asthma is unknown. These asthma patients represent a phenotype that is characterized by low eosinophilic airway inflammation, severe symptoms, moderate obesity and poor response to conventional medicine. Thus, our hypothesis is that regular physical exercise is especially associated with an improvement in asthma control in this phenotype. The aim of this project is to test this hypothesis and to assess whether an improvement is associated with reduced local and systemic inflammation, change in heart function, lung function and/or body composition.

Study design: 40 postmenopausal women with late-onset asthma are recruited via the outpatient clinic at the Respiratory Department at Bispebjerg Hospital and through advertisement. The participants are randomized 1:1 into two groups. One group performs supervised exercise training (spinning) three times per week for 12 weeks while the other group is a control group. Before and after the intervention asthma control, local and systemic inflammation, heart function and body composition is measured.

Results: Analysis will be performed to detect changes within and between the groups before and after intervention. Primary outcome is change in ACQ (Asthma Control Questionnaire). Local and systemic inflammation is measured by changes in bronchial challenge to methacholine, sputum cell count and blood tests. Furthermore, secondary outcomes include change in heart function measured by stress-echocardiography and change in body composition measured by Dual-energy X-ray absorptiometry (DEXA).

Conclusion: There are to date no prospective studies that can support recommendations containing asthma rehabilitation with supervised regular physical activity for postmenopausal women. Thus, this study will provide novel understanding of the importance of physical activity in a chronic disease such as asthma.

Panoramica dello studio

Stato

Terminato

Intervento / Trattamento

Descrizione dettagliata

Overall study design

The study is a single-blinded randomized controlled intervention study. Forty postmenopausal women with late-onset asthma (>16 years at debut) are recruited from the asthma outpatient-clinic at Bispebjerg Hospital or other hospital/practitioner in the region and/or by advertisement. The participants are block-randomized into two groups of 20, where one group is control and the other undergoes a period of regular exercise training. The investigators will be blinded and will not know whether the subjects have trained or not.

Detailed study design

Participants allocated to the exercise training group undergo a training intervention consisting of 45 minutes of intermittent high intensity aerobic spinning training three times per week for 12 weeks. Participants allocated to the control group will continue usual care without training. No changes to current treatment will be made by the investigators on any of the groups.

The training will consist of short periods of high intensity intervals where subjects reach above 80% of maximal oxygen consumption. Spinning sessions will be fully supervised by trained instructors with a bachelor of sports and science or bachelor of medicine and conducted in the Department of Nutrition, Exercise and Sports, University of Copenhagen. Subjects will wear heart rate monitors to ensure adherence to the training protocol. Within two weeks, before and after the intervention, participants from both groups undergo 3 days of testing.

To ensure equal compliance with asthma medication both groups will receive daily electronic reminders. Once a week, all participants will be asked about their compliance to their medication.

Tipo di studio

Interventistico

Iscrizione (Effettivo)

12

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Copenhagen, Danimarca, 2400
        • Respiratory research unit, Bispebjerg University Hospital

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 45 anni a 75 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Femmina

Descrizione

Inclusion Criteria:

  • Late onset asthma (Debut ≥ 16 years of age)
  • ACQ ≥ 1.25
  • Daily treatment for asthma (GINA 2 and above)
  • Age 45 - 75
  • Postmenopausal defined as no menstruation for 6 months, Serum Follicle stimulating hormone >20 International Units per Liter and P-Estradiol nmol/L <0.09
  • BMI 25 - 35
  • Positive bronchial challenge to methacholine, mannitol or positive reversibility to beta2-agonist now or historically
  • Untrained (no participation in vigorous exercise for more than 1 hour per week during the last 2 months)
  • Capable of exercising on a bike

Exclusion Criteria:

  • Unable to speak and understand Danish or English.
  • Current or former smokers (>6 months cessation) with >20 years of daily smoking with 20 cigarettes per day.
  • Other respiratory disease of clinical significance
  • Cardiovascular: Unstable ischemic heart disease, myocardial infarction within the last 12 months, symptomatic heart failure (EF <40%), symptomatic heart arrhythmia (documented with ECG), uncontrolled hypertension (>155/100)
  • Any disorder that is not stable and in the opinion of the investigator could affect the safety of the subject throughout the study
  • Subjects, who by investigators determination, will not be able to adhere to study protocol

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Aerobic exercise intervention
Aerobic exercise by high intensity interval training, 3 times per week for 12 weeks
High Intensity Interval Training (HIIT)
Nessun intervento: Control group
No intervention for 12 weeks

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Asthma control - Asthma Control Questionnaire (ACQ)
Lasso di tempo: -21 to 0 days before intervention and 0 to 14 days post intervention
Changes in Asthma Control Questionnaire (ACQ) 7-point scale (0=no impairment, 6= maximum impairment for symptoms and rescue use)
-21 to 0 days before intervention and 0 to 14 days post intervention

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Heart Rate Variability
Lasso di tempo: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in:

- Heart rate variability

-21 to 0 days before intervention and 0 to 14 days post intervention
Heart rhytm
Lasso di tempo: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in:

- Heart rhythm

-21 to 0 days before intervention and 0 to 14 days post intervention
Heart Rate
Lasso di tempo: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in:

- electrocardiography

-21 to 0 days before intervention and 0 to 14 days post intervention
Heart function - Strain
Lasso di tempo: -21 to 0 days before intervention and 0 to 14 days post intervention

Measured by stress-echocardiography

- Strain

-21 to 0 days before intervention and 0 to 14 days post intervention
Heart function - Ejection fraction
Lasso di tempo: -21 to 0 days before intervention and 0 to 14 days post intervention

Measured by stress-echocardiography

- Ejection fraction

-21 to 0 days before intervention and 0 to 14 days post intervention
Heart function - Tricuspid annular plane systolic excursion
Lasso di tempo: -21 to 0 days before intervention and 0 to 14 days post intervention

Measured by stress-echocardiography

- Tricuspid annular plane systolic excursion

-21 to 0 days before intervention and 0 to 14 days post intervention
Heart function - Right ventricular function
Lasso di tempo: -21 to 0 days before intervention and 0 to 14 days post intervention

Measured by stress-echocardiography

- Right ventricular function

-21 to 0 days before intervention and 0 to 14 days post intervention
Heart function - Pulmonary pressure
Lasso di tempo: -21 to 0 days before intervention and 0 to 14 days post intervention

Measured by stress-echocardiography

- Pulmonary pressure

-21 to 0 days before intervention and 0 to 14 days post intervention
Heart function - Lung covered cor
Lasso di tempo: -21 to 0 days before intervention and 0 to 14 days post intervention

Measured by stress-echocardiography

- Lung covered cor

-21 to 0 days before intervention and 0 to 14 days post intervention
Heart function - Blood pressure
Lasso di tempo: -21 to 0 days before intervention and 0 to 14 days post intervention
Blood pressure
-21 to 0 days before intervention and 0 to 14 days post intervention
Heart function - Cardiac output
Lasso di tempo: -21 to 0 days before intervention and 0 to 14 days post intervention
Cardiac output
-21 to 0 days before intervention and 0 to 14 days post intervention
Heart function - Stroke volume
Lasso di tempo: -21 to 0 days before intervention and 0 to 14 days post intervention
Stroke volume
-21 to 0 days before intervention and 0 to 14 days post intervention
Heart function - Total peripheral resistance
Lasso di tempo: -21 to 0 days before intervention and 0 to 14 days post intervention
Total peripheral resistance
-21 to 0 days before intervention and 0 to 14 days post intervention
Systemic inflammation - Leukocytes + differential cell count count
Lasso di tempo: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Leukocytes + differential cell count count

-21 to 0 days before intervention and 0 to 14 days post intervention
Systemic inflammation - Interleukin 6
Lasso di tempo: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Interleukin 6

-21 to 0 days before intervention and 0 to 14 days post intervention
Systemic inflammation - Interleukin 8
Lasso di tempo: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Interleukin 8

-21 to 0 days before intervention and 0 to 14 days post intervention
Systemic inflammation
Lasso di tempo: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Other interleukins

-21 to 0 days before intervention and 0 to 14 days post intervention
Systemic inflammation - Tumor Necrosis Factor alpha
Lasso di tempo: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Tumor Necrosis Factor alpha

-21 to 0 days before intervention and 0 to 14 days post intervention
Systemic inflammation - Total immunoglobulin E, Specific immunoglobulin E
Lasso di tempo: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

  • Total immunoglobulin E
  • Specific immunoglobulin E
-21 to 0 days before intervention and 0 to 14 days post intervention
Systemic inflammation - high sensitivity c reactive protein
Lasso di tempo: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- high sensitivity c reactive protein

-21 to 0 days before intervention and 0 to 14 days post intervention
Local airway inflammation - Sputum cell count
Lasso di tempo: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Sputum cell count

-21 to 0 days before intervention and 0 to 14 days post intervention
Local airway inflammation - Fraction of exhaled nitric oxide
Lasso di tempo: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Fraction of exhaled nitric oxide

-21 to 0 days before intervention and 0 to 14 days post intervention
Local airway inflammation - Hyperreactivity to inhaled methacholine
Lasso di tempo: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Hyperreactivity to inhaled methacholine

-21 to 0 days before intervention and 0 to 14 days post intervention
Body Composition
Lasso di tempo: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Total body fat

-21 to 0 days before intervention and 0 to 14 days post intervention
Body Composition
Lasso di tempo: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Lean body mass

-21 to 0 days before intervention and 0 to 14 days post intervention
Body Composition
Lasso di tempo: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Muscle mass

-21 to 0 days before intervention and 0 to 14 days post intervention
Body Composition
Lasso di tempo: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Weight

-21 to 0 days before intervention and 0 to 14 days post intervention
Microbiome
Lasso di tempo: -21 to 0 days before intervention and 0 to 14 days post intervention
Changes in the microbiota in sputum, oral cavity and nasal cavity before and after the training intervention
-21 to 0 days before intervention and 0 to 14 days post intervention
Compliance - Foster score
Lasso di tempo: -21 to 0 days before intervention and 0 to 14 days post intervention

Change in

- Foster score Answers describe last weeks medicine use. Answers range form 0/7 - 7/7 with low values being worse.

-21 to 0 days before intervention and 0 to 14 days post intervention
Other asthma related questionnaires - Nijmegen questionnaire
Lasso di tempo: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Nijmegen questionnaire Values range from 0-64 and values below 20 are considered normal.

-21 to 0 days before intervention and 0 to 14 days post intervention
Other asthma related questionnaires - Mini Asthma Quality of Life Questionnaire (miniAQLQ)
Lasso di tempo: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Mini Asthma Quality of Life Questionnaire (miniAQLQ) 7-point Likert scale (7 = not impaired at all - 1 = severely impaired).

-21 to 0 days before intervention and 0 to 14 days post intervention
Other asthma related questionnaires - Hospital Anxiety and Depression Scale (HADS) 2 items with 7 questions regarding anxiety and depression. (0 = no sign of depression/anxiety, 21 = maximal signs of anxiety/depression)
Lasso di tempo: -21 to 0 days before intervention and 0 to 14 days post intervention

Changes in

- Hospital Anxiety and Depression Scale (HADS)

-21 to 0 days before intervention and 0 to 14 days post intervention

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Vibeke Backer, Physician, Respiratory Research Unit, Bispebjerg Hospital

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

12 febbraio 2019

Completamento primario (Effettivo)

1 maggio 2021

Completamento dello studio (Effettivo)

1 maggio 2021

Date di iscrizione allo studio

Primo inviato

9 novembre 2018

Primo inviato che soddisfa i criteri di controllo qualità

19 novembre 2018

Primo Inserito (Effettivo)

20 novembre 2018

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

23 giugno 2021

Ultimo aggiornamento inviato che soddisfa i criteri QC

17 giugno 2021

Ultimo verificato

1 giugno 2021

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • ATOM (Altro identificatore: Radius Health, Inc.)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

Descrizione del piano IPD

Data that support the results of this study will be made available immediately, with no end date, after deidentification and upon reasonable request.

Periodo di condivisione IPD

Immediately after publication with no end date.

Criteri di accesso alla condivisione IPD

Data will be made available upon reasonable request to achieve the aims of the reasonable request.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Prove cliniche su Aerobic exercise

3
Sottoscrivi